NASDAQ:NLNKNewLink Genetics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding NewLink Genetics Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $8.81 +1.03 (+13.24 %) (As of 04/7/2020 08:33 AM ET) Add Compare Share Today's Range$7.81Now: $8.81▼$9.2450-Day Range$0.89MA: $3.46▼$8.8552-Week Range$0.82Now: $8.81▼$3.60Volume38,696 shsAverage Volume600,095 shsMarket Capitalization$328.88 millionP/E RatioN/ADividend YieldN/ABeta1.17 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing Indoximod, an indoleamine-2, 3-dioxygenase (IDO) pathway inhibitor that is in clinical development in combination with other cancer therapeutics for patients with diffuse intrinsic pontine glioma, pediatric brain tumors, acute myeloid leukemia, and melanoma. The company also develops NLG207 in combination with paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer; NLG802, a prodrug of indoximod, which has completed Phase I clinical trial; and NLG919, a direct enzymatic inhibitor. The company has collaboration and license agreement with Genentech Inc. for the development and commercialization of NLG919, as well as a research collaboration for the discovery of next generation IDO/TDO inhibitors; and Merck Sharpe & Dohme Corp. to research, develop, and commercialize rVSV G-ZEBOV GP, an Ebola vaccine product candidate. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for NewLink Genetics. Previous Next 2.8 Community Rank Outperform VotesNewLink Genetics has received 384 “outperform” votes. (Add your “outperform” vote.)Underperform VotesNewLink Genetics has received 307 “underperform” votes. (Add your “underperform” vote.)Community SentimentNewLink Genetics has received 55.57% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about NewLink Genetics and other stocks. Vote “Outperform” if you believe NLNK will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NLNK will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldNewLink Genetics does not currently pay a dividend.Dividend GrowthNewLink Genetics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NewLink Genetics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 12.70% of the stock of NewLink Genetics is held by insiders.Percentage Held by InstitutionsOnly 32.32% of the stock of NewLink Genetics is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of NewLink Genetics is -7.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NewLink Genetics is -7.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNewLink Genetics has a P/B Ratio of 4.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.56 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:NLNK Previous Symbol CUSIP65151110 CIK1126234 Webhttp://www.newlinkgenetics.com/ Phone515-296-5555Debt Debt-to-Equity RatioN/A Current Ratio7.98 Quick Ratio7.98Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$940,000.00 Price / Sales349.87 Cash FlowN/A Price / Cash FlowN/A Book Value$2.11 per share Price / Book4.18Profitability EPS (Most Recent Fiscal Year)($1.03) Net Income$-42,990,000.00 Net Margins-4,592.84% Return on Equity-41.50% Return on Assets-33.95%Miscellaneous Employees55 Outstanding Shares37,330,000Market Cap$328.88 million Next Earnings Date5/13/2020 (Estimated) OptionableOptionable Receive NLNK News and Ratings via Email Sign-up to receive the latest news and ratings for NLNK and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:NLNK Rates by TradingView NewLink Genetics (NASDAQ:NLNK) Frequently Asked Questions How has NewLink Genetics' stock been impacted by COVID-19 (Coronavirus)? NewLink Genetics' stock was trading at $1.2101 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, NLNK shares have increased by 628.0% and is now trading at $8.81. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of NewLink Genetics? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NewLink Genetics in the last year. There are currently 1 sell rating for the stock, resulting in a consensus recommendation of "Sell." View analyst ratings for NewLink Genetics. When is NewLink Genetics' next earnings date? NewLink Genetics is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for NewLink Genetics. How were NewLink Genetics' earnings last quarter? NewLink Genetics Corp (NASDAQ:NLNK) posted its earnings results on Friday, February, 28th. The biotechnology company reported ($0.22) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.28) by $0.06. The biotechnology company had revenue of $0.43 million for the quarter, compared to analyst estimates of $0.25 million. NewLink Genetics had a negative net margin of 4,592.84% and a negative return on equity of 41.50%. View NewLink Genetics' earnings history. Has NewLink Genetics been receiving favorable news coverage? News headlines about NLNK stock have been trending very negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. NewLink Genetics earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutNewLink Genetics. Who are some of NewLink Genetics' key competitors? Some companies that are related to NewLink Genetics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Repligen (RGEN). What other stocks do shareholders of NewLink Genetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other NewLink Genetics investors own include Arbutus Biopharma (ABUS), Inovio Pharmaceuticals (INO), Opko Health (OPK), Synergy Pharmaceuticals (SGYP), SunPower (SPWR), Novavax (NVAX), Sarepta Therapeutics (SRPT), Alibaba Group (BABA), Cara Therapeutics (CARA) and Celldex Therapeutics (CLDX). Who are NewLink Genetics' key executives? NewLink Genetics' management team includes the following people: Dr. Charles J. Link Jr., Co-Founder, Chairman, CEO & Chief Scientific Officer (Age 60)Mr. Nicholas N. Vahanian, Co-Founder, Pres, Chief Medical Officer & Director (Age 52)Dr. Eugene P. Kennedy M.D., FACS, Chief Medical Officer (Age 50)Mr. Brian Wiley, Chief Commercial Officer (Age 51)Mr. Carl W. Langren, CFO & Principal Accounting Officer (Age 64) What is NewLink Genetics' stock symbol? NewLink Genetics trades on the NASDAQ under the ticker symbol "NLNK." How do I buy shares of NewLink Genetics? Shares of NLNK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is NewLink Genetics' stock price today? One share of NLNK stock can currently be purchased for approximately $8.81. How big of a company is NewLink Genetics? NewLink Genetics has a market capitalization of $328.88 million and generates $940,000.00 in revenue each year. The biotechnology company earns $-42,990,000.00 in net income (profit) each year or ($1.03) on an earnings per share basis. NewLink Genetics employs 55 workers across the globe. View additional information about NewLink Genetics. What is NewLink Genetics' official website? The official website for NewLink Genetics is http://www.newlinkgenetics.com/. How can I contact NewLink Genetics? NewLink Genetics' mailing address is 2503 SOUTH LOOP DRIVE, AMES IA, 50010. The biotechnology company can be reached via phone at 515-296-5555 or via email at [email protected] This page was last updated on 4/7/2020 by MarketBeat.com StaffFeatured Article: Initial Public Offering (IPO)
